Welcome!

News Feed Item

Coronary Vasospasm Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Coronary Vasospasm Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/648928/Coronary-Vasospasm-Global-Clinical-Trials-Review-H2-2014.html

Coronary Vasospasm Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Coronary Vasospasm Global Clinical Trials Review, H2, 2014" provides data on the Coronary Vasospasm clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Coronary Vasospasm. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Coronary Vasospasm. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Coronary Vasospasm 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Coronary Vasospasm 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Top Companies Participating in Coronary Vasospasm Therapeutics Clinical Trials 25
Prominent Drugs 26
Clinical Trial Profiles 27
Clinical Trial Overview of Top Companies 27
Pfizer Inc. 27
Clinical Trial Overview of Pfizer Inc. 27
Clinical Trial Overview of Top Institutes / Government 28
Japanese Coronary Spasm Association 28
Clinical Trial Overview of Japanese Coronary Spasm Association 28
Robert Bosch Medical Center 29
Clinical Trial Overview of Robert Bosch Medical Center 29
Kyorin University 30
Clinical Trial Overview of Kyorin University 30
Kumamoto University 31
Clinical Trial Overview of Kumamoto University 31
National Institute of Health and Medical Research 32
Clinical Trial Overview of National Institute of Health and Medical Research 32
University of Nebraska 33
Clinical Trial Overview of University of Nebraska 33
Korea University 34
Clinical Trial Overview of Korea University 34
University Hospital Basel 35
Clinical Trial Overview of University Hospital Basel 35
Washington University School of Medicine 36
Clinical Trial Overview of Washington University School of Medicine 36
University of California, San Francisco 37
Clinical Trial Overview of University of California, San Francisco 37
Five Key Clinical Profiles 38
Appendix 55
Abbreviations 55
Definitions 55
Research Methodology 56
Secondary Research 56
About GlobalData 57
Contact Us 57
Disclaimer 57
Source 57

List of Tables
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Region, 2014* 6
Coronary Vasospasm Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Coronary Vasospasm Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Coronary Vasospasm Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Coronary Vasospasm Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Coronary Vasospasm Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Coronary Vasospasm Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 12
Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 13
Coronary Vasospasm Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Coronary Vasospasm Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 16
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Phase, 2014* 17
Coronary Vasospasm Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 18
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Coronary Vasospasm Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Coronary Vasospasm Therapeutics, Global, Suspended Clinical Trials, 2014* 21
Coronary Vasospasm Therapeutics, Global, Withdrawn Clinical Trials, 2014* 21
Coronary Vasospasm Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Coronary Vasospasm Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 23
Coronary Vasospasm Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Coronary Vasospasm Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 25
Coronary Vasospasm Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 26
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 27
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Japanese Coronary Spasm Association, 2014* 28
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Robert Bosch Medical Center, 2014* 29
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Kyorin University, 2014* 30
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Kumamoto University, 2014* 31
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Health and Medical Research, 2014* 32
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Nebraska, 2014* 33
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Korea University, 2014* 34
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital Basel, 2014* 35
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 36
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 37

List of Figures
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Coronary Vasospasm Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Coronary Vasospasm Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Coronary Vasospasm Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 9
Coronary Vasospasm Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Coronary Vasospasm Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 13
Coronary Vasospasm Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Coronary Vasospasm Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 16
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Phase (%), 2014* 17
Coronary Vasospasm Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 18
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Coronary Vasospasm Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Coronary Vasospasm Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 23
Coronary Vasospasm Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
GlobalData Methodology 56

Read the full report:
Coronary Vasospasm Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/648928/Coronary-Vasospasm-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
We're entering the post-smartphone era, where wearable gadgets from watches and fitness bands to glasses and health aids will power the next technological revolution. With mass adoption of wearable devices comes a new data ecosystem that must be protected. Wearables open new pathways that facilitate the tracking, sharing and storing of consumers’ personal health, location and daily activity data. Consumers have some idea of the data these devices capture, but most don’t realize how revealing and...
"Software-defined storage is a big problem in this industry because so many people have different definitions as they see fit to use it," stated Peter McCallum, VP of Datacenter Solutions at FalconStor Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Unless your company can spend a lot of money on new technology, re-engineering your environment and hiring a comprehensive cybersecurity team, you will most likely move to the cloud or seek external service partnerships. In his session at 18th Cloud Expo, Darren Guccione, CEO of Keeper Security, revealed what you need to know when it comes to encryption in the cloud.
Actian Corporation has announced the latest version of the Actian Vector in Hadoop (VectorH) database, generally available at the end of July. VectorH is based on the same query engine that powers Actian Vector, which recently doubled the TPC-H benchmark record for non-clustered systems at the 3000GB scale factor (see tpc.org/3323). The ability to easily ingest information from different data sources and rapidly develop queries to make better business decisions is becoming increasingly importan...
StackIQ has announced the release of Stacki 3.2. Stacki is an easy-to-use Linux server provisioning tool. Stacki 3.2 delivers new capabilities that simplify the automation and integration of site-specific requirements. StackIQ is the commercial entity behind this open source bare metal provisioning tool. Since the release of Stacki in June of 2015, the Stacki core team has been focused on making the Community Edition meet the needs of members of the community, adding features and value, while ...
Using new techniques of information modeling, indexing, and processing, new cloud-based systems can support cloud-based workloads previously not possible for high-throughput insurance, banking, and case-based applications. In his session at 18th Cloud Expo, John Newton, CTO, Founder and Chairman of Alfresco, described how to scale cloud-based content management repositories to store, manage, and retrieve billions of documents and related information with fast and linear scalability. He addres...
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
Ixia (Nasdaq: XXIA) has announced that NoviFlow Inc.has deployed IxNetwork® to validate the company’s designs and accelerate the delivery of its proven, reliable products. Based in Montréal, NoviFlow Inc. supports network carriers, hyperscale data center operators, and enterprises seeking greater network control and flexibility, network scalability, and the capacity to handle extremely large numbers of flows, while maintaining maximum network performance. To meet these requirements, NoviFlow in...
"delaPlex is a software development company. We do team-based outsourcing development," explained Mark Rivers, COO and Co-founder of delaPlex Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
The competitive landscape of the global cloud computing market in the healthcare industry is crowded due to the presence of a large number of players. The large number of participants has led to the fragmented nature of the market. Some of the major players operating in the global cloud computing market in the healthcare industry are Cisco Systems Inc., Carestream Health Inc., Carecloud Corp., AGFA Healthcare, IBM Corp., Cleardata Networks, Merge Healthcare Inc., Microsoft Corp., Intel Corp., an...
Is your aging software platform suffering from technical debt while the market changes and demands new solutions at a faster clip? It’s a bold move, but you might consider walking away from your core platform and starting fresh. ReadyTalk did exactly that. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, will discuss why and how ReadyTalk diverted from healthy revenue and over a decade of audio conferencing product development to start an innovati...
Continuous testing helps bridge the gap between developing quickly and maintaining high quality products. But to implement continuous testing, CTOs must take a strategic approach to building a testing infrastructure and toolset that empowers their team to move fast. Download our guide to laying the groundwork for a scalable continuous testing strategy.
Early adopters of IoT viewed it mainly as a different term for machine-to-machine connectivity or M2M. This is understandable since a prerequisite for any IoT solution is the ability to collect and aggregate device data, which is most often presented in a dashboard. The problem is that viewing data in a dashboard requires a human to interpret the results and take manual action, which doesn’t scale to the needs of IoT.